Stay updated with breaking news from Van Naarden. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Eli Lilly’s Jaypirca is now approved for treating three types of blood cancers. While Jaypirca blocks a target already addressed by other cancer therapies, the Lilly molecule does it in a way that sets it apart from the rest of its drug class.
The FDA has granted an accelerated approval to pirtobrutinib for the treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who have received at least two prior lines of therapy, including a BTK inhibitor and a BCL2 inhibitor.
Waste management industry news, voices and jobs for professionals. Optimized for your mobile phone.
The company entered into a buyout agreement with Eli Lilly.
American pharmaceutical company Eli Lilly plans to acquire cancer therapy firm Point Biopharma Global, the companies announced Tuesday, an expansion that comes as manu...